Table 1 Sample description.
Index | Age | Gender | Ethnicity | Comorbidities | Immunosuppressive |
---|---|---|---|---|---|
MIS-C | |||||
M1 | 0–5 | Male | Hispanic | None | None |
M2 | 6–11 | Female | Hispanic | None | None |
M3 | 12–17 | Male | Black | Asthma | None |
M4 | 0–5 | Female | Hispanic | None | None |
M5 | 18–23 | Male | Hispanic | Asthma | None |
M6 | 12–17 | Male | Hispanic | Appendicitis | None |
M7 | 12–17 | Female | Black | MDD, PTSD | None |
M8 | 6–11 | Female | Hispanic | None | None |
Pediatric COVID-19 | |||||
C1 | 6–11 | Female | Hispanic | B-cell ALL | Chemotherapy |
C2 | 18–23 | Male | Hispanic | Asthma | None |
C3 | 0–5 | Male | Hispanic | Autoimmune Anemia | Steroids |
C4 | 18–23 | Female | Not Reported | Pineoblastoma | Chemotherapy |
C5 | 18–23 | Male | Hispanic | B-cell ALL | Chemotherapy |
C6 | 6–11 | Male | White | Gastrochisis | Tacrolimus |
C7 | 12–17 | Male | Black | IBD | Infliximab |
Healthy controls | |||||
H1 | 24–29 | Female | Asian | None | None |
H2 | 35–40 | Male | White | None | None |
H3 | 24–29 | Female | White | None | None |
H4 | 35–40 | Female | White | None | None |